Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

December 31, 2009

Conditions
HIV-1
Interventions
BIOLOGICAL

HIV DNA Vaccine

0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.

Trial Locations (1)

1188

South Hospital, Stockholm

All Listed Sponsors
collaborator

European Union

OTHER

collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Läkare mot AIDS Forskningsfond

UNKNOWN

lead

Swedish Institute for Infectious Disease Control

OTHER

NCT01140139 - Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions | Biotech Hunter | Biotech Hunter